S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.44 (-0.88%)
AAPL   175.97 (+0.53%)
MSFT   423.36 (-1.07%)
META   518.75 (-0.84%)
GOOGL   159.10 (-0.19%)
AMZN   187.98 (-0.57%)
TSLA   172.52 (-1.19%)
NVDA   898.26 (-0.87%)
AMD   163.74 (-3.96%)
NIO   4.35 (-2.47%)
BABA   72.90 (-2.61%)
T   16.35 (-0.43%)
F   12.83 (-1.61%)
MU   125.08 (-1.91%)
GE   156.50 (-0.57%)
CGC   8.21 (+0.74%)
DIS   116.37 (-0.67%)
AMC   2.74 (-2.14%)
PFE   26.21 (-0.49%)
PYPL   65.48 (-0.49%)
XOM   123.00 (+0.99%)

Ingevity (NGVT) Stock Price, News & Analysis

$46.76
-0.12 (-0.26%)
(As of 09:30 AM ET)
Today's Range
$46.76
$46.76
50-Day Range
$42.69
$49.17
52-Week Range
$36.66
$74.74
Volume
2,854 shs
Average Volume
224,382 shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.75

Ingevity MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.3% Upside
$48.75 Price Target
Short Interest
Healthy
1.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
40.82%
From $3.65 to $5.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Basic Materials Sector

415th out of 498 stocks

Chemicals & Allied Products Industry

37th out of 42 stocks

NGVT stock logo

About Ingevity Stock (NYSE:NGVT)

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products for use in gasoline vapor emission control systems in cars, motorcycles, trucks, and boats. This segment also produces other activated carbon products for food, water, beverage, and chemical purification applications. The Performance Chemicals segment consists of road technologies and industrial specialties. This segment's products are used in pavement construction, pavement preservation, pavement reconstruction and recycling, road markings, agrochemical dispersants, paper chemicals, and other industrial uses. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices. It serves automotive parts and components manufacturers through sales representatives and distributors. The company was formerly known as WestRock Company, Specialty Chemicals Business and changed its name to Ingevity Corporation in September 2015. Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.

NGVT Stock Price History

NGVT Stock News Headlines

Ingevity (NYSE: NGVT)
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
NGVT Jun 2024 50.000 call
NGVT Apr 2024 45.000 call
Ingevity price target raised by $7 at Wells Fargo, here's why
Ingevity: Hold Rating Amidst Transition and Macroeconomic Uncertainties
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Ingevity (NGVT) Q4 Earnings and Revenues Beat Estimates
Ingevity earnings: here's what Wall Street expects
Ingevity's Earnings Outlook
Ingevity Corp.
NGVT: Raising target price to $40.00
See More Headlines
Receive NGVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/12/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
N/A
Previous Symbol
NASDAQ:NGVT
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.75
High Stock Price Target
$53.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
-0.60%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$7.34 per share
Book Value
$17.43 per share

Miscellaneous

Free Float
35,882,000
Market Cap
$1.70 billion
Optionable
Optionable
Beta
1.85
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. John C. Fortson (Age 57)
    President, CEO & Director
    Comp: $1.29M
  • Ms. Mary Dean Hall (Age 66)
    Executive VP & CFO
    Comp: $658.77k
  • Ms. Stacy Lancaster Cozad (Age 53)
    Executive VP, General Counsel & Secretary
    Comp: $615.75k
  • Mr. Stuart Edward Woodcock Jr.Mr. Stuart Edward Woodcock Jr. (Age 58)
    Executive VP & President of Performance Materials
    Comp: $823.8k
  • Mr. Richard A. White Jr. (Age 61)
    Senior VP & President of Performance Chemicals
    Comp: $575.57k
  • Mr. Phillip John Platt (Age 43)
    VP, Chief Accounting Officer & Business Transformation Lead
  • John E. Nypaver Jr.
    VP of Investor Relations & Treasurer
  • Caroline Monahan
    Director of Communications
  • Ms. Christine Stunyo (Age 45)
    Senior VP & Chief Human Resources Officer
  • Mr. Steven P. Hulme (Age 55)
    Senior VP & President of Advanced Polymer Technologies

NGVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Ingevity stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings
or view top-rated stocks.

What is Ingevity's stock price target for 2024?

4 analysts have issued 1-year price objectives for Ingevity's stock. Their NGVT share price targets range from $43.00 to $53.00. On average, they expect the company's share price to reach $48.75 in the next year. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for NGVT
or view top-rated stocks among Wall Street analysts.

How have NGVT shares performed in 2024?

Ingevity's stock was trading at $47.22 at the start of the year. Since then, NGVT stock has decreased by 1.0% and is now trading at $46.76.
View the best growth stocks for 2024 here
.

When is Ingevity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NGVT earnings forecast
.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) posted its quarterly earnings results on Wednesday, February, 21st. The company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.34. The business earned $371.70 million during the quarter, compared to the consensus estimate of $336.74 million. Ingevity had a negative net margin of 0.32% and a positive trailing twelve-month return on equity of 20.75%. The business's revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period last year, the firm posted $0.57 EPS.

What ETFs hold Ingevity's stock?
What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.4 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

Who are Ingevity's major shareholders?

Ingevity's stock is owned by many different retail and institutional investors. Top institutional shareholders include Salem Investment Counselors Inc. (0.28%) and Moody National Bank Trust Division (0.06%). Insiders that own company stock include Erik Spencer Ripple, Phillip John Platt, Richard Allen White Jr and Stuart Edward Jr Woodcock.
View institutional ownership trends
.

How do I buy shares of Ingevity?

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NGVT) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners